Catalent, Inc., is an American multinational company, and a subsidiary of Novo Holdings A/S since 2024. It is headquartered in Somerset, New Jersey. From Wikipedia
The investment arm of Novo Nordisk doubled its 2024 income to €8 billion, driven by obesity drug dividends, while focusing on Asian expansion to counter challenges.
